Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass General
CRISPR Therapeutics $CRSP is allying with some top immuno-oncology researchers at Mass General to collaborate on some new gene editing working aimed at creating a new and better generation of T cell therapies.
The biotech — based in Switzerland with a big research group in Cambridge, MA — has tied the partnership knot with Marcela V. Maus, who runs the cellular immunotherapy group at Mass General. She’ll be using the biotech’s pioneering CRISPR/Cas9 tech to see how it works in building a new-and-improved T cell therapy — just as the original models appear poised to hit the market later in the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
